252 related articles for article (PubMed ID: 28039754)
21. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
22. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
23. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
[TBL] [Abstract][Full Text] [Related]
24. Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis.
Pavlopoulou ID; Poulopoulou S; Melexopoulou C; Papazaharia I; Zavos G; Boletis IN
BMC Infect Dis; 2015 Jul; 15():285. PubMed ID: 26204926
[TBL] [Abstract][Full Text] [Related]
25. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
26. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial.
Tyring SK; Lee P; Hill GT; Silverfield JC; Moore AY; Matkovits T; Sullivan-Bolyai J
J Med Virol; 2017 Jul; 89(7):1255-1264. PubMed ID: 27943311
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Incidence of Varicella Zoster Virus Disease in Adults Receiving Single-Unit Cord Blood Transplantation.
Fukushi K; Konuma T; Monna-Oiwa M; Isobe M; Kato S; Kuroda S; Takahashi S; Nannya Y
Transplant Cell Ther; 2022 Jun; 28(6):339.e1-339.e7. PubMed ID: 35364334
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
29. Low-Dose Acyclovir Prophylaxis for
Fei N; Shah N; Cumpston A; Wen S; Ross KG; Craig M; Kanate AS
Clin Hematol Int; 2019 Jun; 1(2):101-104. PubMed ID: 34595417
[No Abstract] [Full Text] [Related]
30. Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster: comment on "incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster".
Green CB; Stratman EJ
Arch Dermatol; 2011 Aug; 147(8):908. PubMed ID: 21844449
[No Abstract] [Full Text] [Related]
31. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
[TBL] [Abstract][Full Text] [Related]
32. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study.
Lapolla W; Digiorgio C; Haitz K; Magel G; Mendoza N; Grady J; Lu W; Tyring S
Arch Dermatol; 2011 Aug; 147(8):901-7. PubMed ID: 21482862
[TBL] [Abstract][Full Text] [Related]
33. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.
Su SH; Martel-Laferrière V; Labbé AC; Snydman DR; Kent D; Laverdière M; Béliveau C; Logvinenko T; Cohen S; Lachance S; Kiss T; Roy J
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1012-7. PubMed ID: 20977944
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors for herpes zoster following heart transplantation.
Koo S; Gagne LS; Lee P; Pratibhu PP; James LM; Givertz MM; Marty FM
Transpl Infect Dis; 2014 Feb; 16(1):17-25. PubMed ID: 24147978
[TBL] [Abstract][Full Text] [Related]
35. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
36. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
37. Herpes zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation.
Abbasov E; Metzner B; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voß A; Köhne CH
Eur J Haematol; 2022 Sep; 109(3):298-304. PubMed ID: 35687019
[TBL] [Abstract][Full Text] [Related]
38. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
Bastidas A; de la Serna J; El Idrissi M; Oostvogels L; Quittet P; López-Jiménez J; Vural F; Pohlreich D; Zuckerman T; Issa NC; Gaidano G; Lee JJ; Abhyankar S; Solano C; Perez de Oteyza J; Satlin MJ; Schwartz S; Campins M; Rocci A; Vallejo Llamas C; Lee DG; Tan SM; Johnston AM; Grigg A; Boeckh MJ; Campora L; Lopez-Fauqued M; Heineman TC; Stadtmauer EA; Sullivan KM;
JAMA; 2019 Jul; 322(2):123-133. PubMed ID: 31287523
[TBL] [Abstract][Full Text] [Related]
39. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
Boeckh M; Kim HW; Flowers ME; Meyers JD; Bowden RA
Blood; 2006 Mar; 107(5):1800-5. PubMed ID: 16282339
[TBL] [Abstract][Full Text] [Related]
40. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
